The HLA typing market size is estimated to be USD 1,458.12 million in 2022 and is expected to witness a CAGR of 6.87% during the forecast period 2023-2033. Rising strategic initiatives by key market players and surge in incidence are factors contributing to the market growth. Additionally, increasing need for organ transplantation and the widespread use of human leukocyte antigen (HLA) testing in pharmacogenetics are supporting the market growth. However, high price of gene treatments and potential insertional mutagenesis is expected to hinder the growth.

Rising strategic initiatives by key market players is expected to fuel the market growth during the forecast period. For instance, Werfen SA stated in November 2022 that it will begin the process of acquiring Immuncor Inc. for USD 2 billion. The acquiring company views Immuncor Inc. as a suitable complement to its current transplant and blood product offerings. Human leukocyte antigen testing software from Immmuncor offers quick analysis of gene sequencing. Werfen is anticipated to generate more than USD 2.25 (EUR 2.2) billion in revenue after the acquisition, with a total of 7 technological centres and about 7,000 people. Through distributors, this strategy is anticipated to help Werfen establish a direct presence in more than 30 countries and 100 territories.

Surge in incidence of chronic disease is predicted to propel the market growth during the projected period. The sedentary lifestyle, including smoking, inactivity, and an unhealthy diet is responsible for the surge in incidence of chronic disease. Organ failure can be caused by a number of chronic conditions, including diabetes, polycystic kidney disease, lupus, cirrhosis, coronary artery disease, cardiomyopathy, and heart failure. By 2030, the World Health Organization (WHO) predicts that chronic disease-related fatalities will account for 70% of all deaths and 56% of all disease burden.

Segmentation

By Product

The market is categorized into reagents & consumables, instruments, and software & services. In the global market, the reagents & consumables segment accounted for the largest revenue share in 2022 owing to the fact that variety of diagnostic test kits, including HLA typing, use the HLA reagents and consumables as complementing products to improve the precision and efficiency of diagnoses. Healthcare, clinical, and the pharmaceutical industries are the primary users of reagents, according to Thermo Fisher Scientific Inc.’s 2021 annual report. Players from adjacent or related markets are likely to be drawn to the area due to its exponential expansion, allowing them to create resource synergies and increase profits. For instance, Genome Diagnostics BV (GenDx), a major participant in the HLA typing market with a significant presence in the U.S. and Europe, was acquired by Eurobio Scientific in August 2022. GenDx creates and markets a comprehensive HLA typing system that includes training materials, supporting software, and reagents for sequencing-based HLA typing.

By Technique

The market is divided into sequenced-based molecular assay, molecular assay and non-molecular assay. In 2022, the molecular assay segment accounted for the highest revenue share due to the fact that most popular method for HLA typing uses molecular techniques including massively parallel sequencing or hybridization methods based on probes. Numerous genetic techniques, including PCR followed by massively parallel sequencing, can be used to do molecular typing. Depending on the donors and the organs that will be transplanted, different techniques are used. For instance, molecular class I and class II HLA loci are done for deceased donors, while high-resolution molecular class I HLA loci are advised for hematopoietic stem cell transplantation. The market is experiencing a rise in the use of next-generation sequencing for human leukocyte antigen typing, which is driving up the need for assays based on sequencing of molecules. For instance, a group of scientists created a high-resolution assay for HLA typing by RNA sequencing in June 2022. This assay may provide precise HLA allele-specific transcript expression and HLA genotyping in 7 to 8 hours.

By Application

The market is segregated into research and diagnosis. In the global market, the diagnosis segment accounted for the largest revenue share in 2022 owing to the fact that Behcet’s disease opens the way for the market for human leukocyte antigen typing to grow rapidly. Mylab Discovery Solutions recently announced the release of the DiscoverSeries HLAB*27 detection kit for the diagnosis of ankylosing spondylitis. The demand for molecular diagnostic tests has increased due to their favourable outcomes. Similar to this, NeoGenomics Laboratories stated in March 2022 that it has received U.S. FDA approval for employing HLA typing for companion diagnostics. The manufacturer predicts a rise in demand for HLA typing and related companion diagnostic assays for a variety of treatments.

By End Use

The market is segmented into hospitals and transplant centers, commercial service providers, and research labs & academic institutes. In 2022, the hospitals and transplant centers segment accounted for the largest revenue share owing to rising number of transplantations. There are about 147 hospitals and transplant centres in the US that perform liver transplants. Around 181 applicants got transplants from deceased donors and 1 from living donors between January 2021 and December 2021 at Houston Methodist Hospital. Similar to Stanford Health Care, 103 and 164 transplants were completed within the same time period at VCU Health System Authority, VCUMC. Additionally, it is projected that the expanding HLA typing services offered by academic and research institutions will significantly impacts the market’s estimated value. For instance, the University of Rochester Medical Center Rochester provides thorough services in cross-matching, HLA typing, and antibody testing at several degrees of resolution that can be customized to the client’s needs. As a result, among these end users, there is an increasing need for service providers for drug sensitivity testing, transplantation programmes, and eligibility screening for the vaccine.

Regional Markets

In 2022, North America region accounted for the highest revenue in the HLA typing market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of wide range of academic institutions and research facilities in the area and together with the rising incidence of genetic disorders. Additionally, companies and the government are concentrating on improvements in organ transplant. Asia Pacific is predicted to have the industry’s fastest expansion due to improved health care facility infrastructure, well-designed reimbursement policies, and rising economic growth. Laboratories with cutting-edge technology will increase the market together with the expanding availability of trained workers and transplant hospitals.

Competitor Insights

Some of the key players operating in the HLA typing market are Bio-Rad Laboratories Inc., Qiagen N.V., Omixon Inc., GenD, TBG Diagnostics Limited, Illumina Inc., Dickinson and Company, Takara Bio Inc., F. Hoffman-La Roche Limited, Thermo Fisher Scientific Inc., and Pacific Biosciences.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, the transplant business CareDx, Inc. announced in October 2022 that it would present its research on the recently developed next-generation sequencing HLA typing kits for hematopoietic stem cell transplantation. The tool is estimated to boost lab workers match transplant candidates as donors and recipients.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, technique, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: HLA Typing Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Reagents & Consumables
• Instruments
• Software & Services

Technique (Revenue, USD Million), 2022 – 2033

• Sequenced-based Molecular Assay
• Molecular Assay
• Non-Molecular Assay

Application (Revenue, USD Million), 2022 – 2033

• Research
• Diagnosis

End Use (Revenue, USD Million), 2022 – 2033

• Hospitals and Transplant Centers
• Commercial Service Providers
• Research Labs & Academic Institutes

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA